Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Stem Cells & Perinatal Therapies

Cell and perinatal products: promise, evidence, quality and clinical limitations.

Adjacent questions · A rheumatology perspective

Rheumatology & Beyond

Food, aesthetic medicine, peptides, and the questions that cross into rheumatology.

Questions, explained

Open a question to read the answer and explore further.

Nutrition · In depth

If I eat perfectly, can I stop my arthritis medication?

Explore the evidence, the open questions, and the full nutrition series.Open the nutrition guideClose the nutrition guide
By Olga Goodman, MDLink to this question ↗

The short answer

Better food can improve health and sometimes disease activity. Reducing treatment depends on sustained disease control, not on how strictly someone follows a diet. “Perfect eating” is neither a medical target nor a test of willpower.

Evidence & treatment decisions

In the two-year Plants for Joints follow-up, 17 of 39 completers taking antirheumatic medicines reduced or stopped them; 12 increased treatment. This uncontrolled follow-up had substantial dropout. It cannot establish an individual’s chance of stopping medication through diet. The original programme also included movement and stress management.

Plants for Joints randomised 83 people: a 16-week diet, exercise and stress programme improved DAS28 by 0.9 points more than usual care. ADIRA tested an anti-inflammatory diet in a crossover trial; its primary adjusted comparison was not statistically significant. These results support potential benefit, with uncertainty about diet’s independent effect.

First name the drug and its purpose. Needing less occasional pain relief is different from reducing a medicine that prevents joint damage. For rheumatoid arthritis, record the duration of remission, swollen joints, relevant blood results, flares and steroid use. Normal CRP alone does not establish remission; less pain alone does not establish absence of inflammation. Keep dates of dietary and medication changes separate so the result remains interpretable.

Current EULAR guidance allows cautious dose reduction in sustained remission, while complete cessation often leads to flare. A useful treatment review therefore needs a specific medicine, a measured state of disease control, a stepwise plan and a plan for recurrence. Nutrition can help someone reach that discussion; it cannot supply those missing measurements.

Sources & further reading
Try a short exercise: What does this advice actually promise?
“I felt better after changing my diet.”
What else changed, and how was improvement measured?
“This food reduces inflammation.”
In which condition, in what study, and with which outcome?
“You can stop your medication.”
What evidence supports that decision for this disease, and how will it be monitored?

These are hypothetical claims. Open a card to find a useful question to ask.

General educational information. Individual assessment and treatment decisions belong with your healthcare team.

Reprinting and copying are permitted only with credit to Olga Goodman, MD and a link to the original publication. Original publication

Peptides & individual decisions3 min read

Could peptide therapy help me—and who should guide it?

I am in favor of their considered use: a specific treatment, a clear purpose and the right patient.Read the answerClose the answer
By Olga Goodman, MDLink to this question ↗

I am in favor of using peptide therapies when there is a clear reason to choose a particular treatment for a particular person. The important questions are which peptide, for whom, for what purpose, and on what evidence. Those questions deserve a serious clinical discussion.

“Peptide therapy” is a broad description, not one treatment with one set of benefits and risks. Evidence for a particular substance, preparation and indication cannot simply be transferred to every other product carrying the same label. I would want to understand the proposed goal before discussing a course of injections: what problem are we trying to change, and how would we know whether we had helped?

For someone with a rheumatic disease, that discussion needs the clinical context: the diagnosis, current disease activity, relevant organ involvement, medicines and supplements, reproductive plans, and the outcome the person actually wants. These are the questions I would use to assess whether a proposal makes sense, what information is missing and when the answer should be no.

Being able to administer an injection is different from being qualified to select and supervise the treatment. A quick recommendation from someone offering an injection is not an individualized assessment. The person guiding the decision needs relevant clinical expertise, a clear rationale and responsibility for follow-up—not simply access to a product.

The evidence and uncertainty must remain visible. For example, FDA identifies limited safety information and concerns about immune reactions and impurities for compounded BPC-157. Those concerns belong in a discussion of that compound; they are neither proof of benefit nor a reason to treat every peptide as identical. FDA: information on specific compounded substances.

For an individual person, selection is a separate, private, case-specific discussion. It should cover the exact option, alternatives, expected benefit, uncertainties, monitoring and stopping criteria. A public article can explain that approach; choosing a molecule, dose, route or course requires the individual assessment.

The question I welcome is: “Could a specific peptide-based approach have a justified place in my care?” Bring the product name, the proposed purpose and the claims you have been given. That creates a useful starting point for an informed conversation.

Try a short exercise: Prepare for an individual discussion
The purpose
“The problem I want to address is ___; a meaningful improvement would be ___.”
The exact proposal
“This is the product, proposed use and evidence I have been given.”
Expertise and follow-up
“Who can assess its place in my care, monitor the outcome and define when to stop?”

Use these prompts to prepare for a conversation with your healthcare team. No score or diagnostic result.

General educational information. Individual assessment and treatment decisions belong with your healthcare team.

Reprinting and copying are permitted only with credit to Olga Goodman, MD and a link to the original publication. Original publication

About this collection

Some of the most interesting questions cross the boundaries of a specialty. I examine specific interventions, tests, and claims through a rheumatology perspective: what is proposed, what the evidence can answer, and how the diagnosis, current treatment, and individual goals change the discussion.

Functional medicine: nutrition, lifestyle, the microbiome, supplements, and expanded testing belong here when there is a specific question to examine.

Professional reading · English

Latest in Rheumatology & Beyond

New essays and evidence reviews will appear here as they are published. The topics above describe the scope of this developing collection.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Aesthetic medicineFunctional medicinePeptidesRheumatologySystemic disease